NU7441 (KU-57788)

Catalog No.S2638

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.

Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

NU7441 (KU-57788) Chemical Structure

NU7441 (KU-57788) Chemical Structure
Molecular Weight: 413.49

Validation & Quality Control

Customer Product Validation(4)

Quality Control & MSDS

Related Compound Libraries

NU7441 (KU-57788) is available in the following compound libraries:

DNA-PK Inhibitors with Unique Features

  • Non-specific DNA-PK Inhibitor

    PI-103 DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.

  • Most Potent DNA-PK Inhibitor

    PIK-75 DNA-PK, IC50=2 nM.

  • Newest DNA-PK Inhibitor

    KU-0060648 Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

  • Classic DNA-PK Inhibitor

    NU7026 Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Product Information

  • Compare DNA-PK Inhibitors
    Compare DNA-PK Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.
Targets DNA-PK [1]
(Cell-free assay)
mTOR [1]
(Cell-free assay)
PI3K [1]
(Cell-free assay)
ATM [1]
(Cell-free assay)
ATR [1]
(Cell-free assay)
IC50 14 nM 1.7 μM 5 μM >100 μM >100 μM
In vitro NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. [2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. [3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. [4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. [5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H1770NWHTbpJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\FT2lEPTB;MD6wNlE1OyEQvF2=M3jJTHNCVkeHUh?=
A172MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTBwMUWzNVYh|ryPMkjvV2FPT0WU
NCI-H526MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2j3bWlEPTB;MD6yPFQxPyEQvF2=MUjTRW5ITVJ?
HDLM-2NXPIZWN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHCTWM2OD1yLkOyN|Q2KM7:TR?=MYrTRW5ITVJ?
HuO-3N1MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TT[2lEPTB;MD60OlY{PiEQvF2=M{\oUXNCVkeHUh?=
NCI-SNU-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PNO2lEPTB;MD62NFk6PCEQvF2=M1;hWXNCVkeHUh?=
SK-N-ASNUDUTXU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHRWHpDUUN3ME2wMlYzOjF4IN88US=>NH75SXJUSU6JRWK=
LoVoMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33DUGlEPTB;MD64Olc1QSEQvF2=MX7TRW5ITVJ?
LAMA-84M{LDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnycVhmUUN3ME2wMlk5QDN|IN88US=>M1rPWXNCVkeHUh?=
CTB-1Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1z0NmlEPTB;MT6xNVU1PiEQvF2=NF\3UYhUSU6JRWK=
KP-N-YSM1HxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\OTWM2OD1zLkG0NlMyKM7:TR?=NXz0TZM1W0GQR1XS
HHMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPQPXZKSzVyPUGuNVgxQTNizszNMVrTRW5ITVJ?
CHL-1M4L5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDsUYhuUUN3ME2xMlIyOzZ6IN88US=>Mmr2V2FPT0WU
NB7MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPwTWM2OD1zLkK0O|Q2KM7:TR?=M1G4SnNCVkeHUh?=
HL-60NFGxT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljnTWM2OD1zLkO4NVkh|ryPMXzTRW5ITVJ?
639-VNYXyVHQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fwN2lEPTB;MT60OFEzQCEQvF2=MYPTRW5ITVJ?
NCI-H1793NWDO[mJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTFwNEW4OEDPxE1?NULNdnM1W0GQR1XS
NEC8NXLFOYRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmj0TWM2OD1zLkW1N|Uh|ryPNE\SNlZUSU6JRWK=
PA-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELQZZBKSzVyPUGuOVgzQTRizszNMl;lV2FPT0WU
D-423MGMlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEW3V41KSzVyPUGuOlk{PjFizszNMk\TV2FPT0WU
NCI-H292M2XrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrj[YJKSzVyPUGuO|QxOTNizszNMme5V2FPT0WU
SK-MEL-1Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHux[5RKSzVyPUGuO|k1PzlizszNM2rUeHNCVkeHUh?=
LB2241-RCCM4DocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTJwMUSxOFYh|ryPMnWwV2FPT0WU
SK-MEL-3MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTJwMU[0PUDPxE1?MVHTRW5ITVJ?
MHH-PREB-1M1SxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLWWmxGUUN3ME2yMlE3PjB7IN88US=>NXTuTYZpW0GQR1XS
BFTC-905NYTHTVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHETWM2OD1{LkG2Olg4KM7:TR?=NGfGcXFUSU6JRWK=
Ramos-2G6-4C10M3:5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;yTWM2OD1{LkG5PVA6KM7:TR?=MX7TRW5ITVJ?
G-361M37r[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPoR|hkUUN3ME2yMlIyPjhizszNNHXibJVUSU6JRWK=
MOLT-4NFuwZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTJwMkG4PFgh|ryPNF\vZmFUSU6JRWK=
DELNH3jUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrrZ3ZKSzVyPUKuN|U2PjRizszNMnu0V2FPT0WU
MV-4-11MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2D2WWlEPTB;Mj6zO|M6KM7:TR?=MWXTRW5ITVJ?
SK-NEP-1MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M364[GlEPTB;Mj6zPFc5OyEQvF2=NI\tbmRUSU6JRWK=
RS4-11MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTJwNU[wNlMh|ryPMkHvV2FPT0WU
HuH-7M4m0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTJwNU[3NFIh|ryPNYHwbG02W0GQR1XS
A101DMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PCVWlEPTB;Mj62NVM{QCEQvF2=NIfNeoNUSU6JRWK=
KG-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTuTWM2OD1{Lk[3PVI1KM7:TR?=NGXr[HNUSU6JRWK=
KALS-1NHf4[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DmeGlEPTB;Mj62PVY{OyEQvF2=Mn3PV2FPT0WU
VMRC-RCZNVfH[GNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV30R5JXUUN3ME2yMlc4OzJ6IN88US=>M1O1dnNCVkeHUh?=
SK-UT-1NVPIS45iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXBTWM2OD1|LkG1N|Eh|ryPNEiwSJVUSU6JRWK=
SW962MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXlWodKSzVyPUOuNlA{PTJizszNNGK3OpRUSU6JRWK=
DBTRG-05MGM3jyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHO5U4lKSzVyPUOuNlgxQDVizszNNVvMPW1NW0GQR1XS
PANC-08-13NY\pU5J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnf2TWM2OD1|LkSxNlc5KM7:TR?=NX\2UIhjW0GQR1XS
QIMR-WILM1;JXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTNwNEGzOFEh|ryPNVPXVYNiW0GQR1XS
SK-MEL-30M2DnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjaVnBKSzVyPUOuOFI2QThizszNNH;wOFhUSU6JRWK=
697NV64W5pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTNwNES5PVMh|ryPMoDWV2FPT0WU
NYNFy1OlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1H5d2lEPTB;Mz60OVAzOiEQvF2=NF;3c29USU6JRWK=
ES7NGrJU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnjeVMxUUN3ME2zMlQ3PzJ7IN88US=>MXXTRW5ITVJ?
JVM-3Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLiRmtKSzVyPUOuOFgxPzdizszNMWTTRW5ITVJ?
U031Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGqy[INKSzVyPUOuOVk{PjhizszNMV7TRW5ITVJ?
BHT-101MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTrcpVKSzVyPUOuOVk6QDVizszNNIrFXVNUSU6JRWK=
8305CMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfyTWM2OD1|Lk[xO|M3KM7:TR?=NH7wSmJUSU6JRWK=
MG-63M{P6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTNwNkK2O|Yh|ryPNF\oRldUSU6JRWK=
NOS-1M2HNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfKOoNKSzVyPUOuOlU{OTJizszNM3rKWHNCVkeHUh?=
YH-13NF[w[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGix[VRKSzVyPUOuPFcyQDlizszNMnG5V2FPT0WU
LXF-289MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nldWlEPTB;Mz65NVA1OSEQvF2=M4TleXNCVkeHUh?=
GOTONFrLUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\OXWlEPTB;Mz65NVQ6KM7:TR?=MnvnV2FPT0WU
EKVXNYnNclRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;ZTWM2OD12LkKyOVI1KM7:TR?=NXPrTXFkW0GQR1XS
CAL-51MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIO5cIxKSzVyPUSuNlQ5PTRizszNNWHoZVRDW0GQR1XS
AN3-CANI[3VGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTRwMkW4NVMh|ryPMYnTRW5ITVJ?
IA-LMMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLrV5VKSzVyPUSuNlc6OzVizszNM{j4bXNCVkeHUh?=
KU-19-19Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1z0PWlEPTB;ND6zNlkzOSEQvF2=NFPNXHBUSU6JRWK=
A704NYPmPGZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFP1bppKSzVyPUSuOFA5QDhizszNM2rCZXNCVkeHUh?=
RH-18NW\yc3NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTRwNES5OVMh|ryPMlHrV2FPT0WU
IST-MEL1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1G5fWlEPTB;ND61PFI3OyEQvF2=M13GcHNCVkeHUh?=
LU-134-AM3;4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTRwNUm2PFUh|ryPM1j0dXNCVkeHUh?=
SF126MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{f1S2lEPTB;ND62NFcyPSEQvF2=M1\WRXNCVkeHUh?=
EFO-27MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TmcGlEPTB;ND62OlUzPSEQvF2=M3Pr[XNCVkeHUh?=
SN12CNVLiOHZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TYOGlEPTB;ND63NVg6QCEQvF2=MVXTRW5ITVJ?
L-363M2jhNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTRwN{exNVYh|ryPMWPTRW5ITVJ?
MEL-HONEPvO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3Tq[mlEPTB;ND63O|k5QSEQvF2=MWDTRW5ITVJ?
TYK-nuMmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2H6XWlEPTB;ND64NFEzQCEQvF2=NIK4O|FUSU6JRWK=
MDA-MB-415MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moe1TWM2OD13LkCwN|E1KM7:TR?=MWfTRW5ITVJ?
HCC70NXju[oNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M165VGlEPTB;NT6wN|k{QSEQvF2=Ml;4V2FPT0WU
IGROV-1NGf1O3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M334NmlEPTB;NT6yOVI6OiEQvF2=NIDqfXVUSU6JRWK=
NCI-H1355NV7ZVmh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljWTWM2OD13LkK5OkDPxE1?M3\EPHNCVkeHUh?=
23132-87M4LzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlyyTWM2OD13LkOyNFI1KM7:TR?=NFvvNYJUSU6JRWK=
NB69NInNTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknGTWM2OD13LkOyOFIh|ryPM3zPZXNCVkeHUh?=
HSC-2NEH4UnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\FTWM2OD13LkSxO|c{KM7:TR?=MoSyV2FPT0WU
KYSE-410NEP4TJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvjSY9KSzVyPUWuOFc3OzZizszNNUjhcIdwW0GQR1XS
GCIYMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2T2[mlEPTB;NT61NVM4QCEQvF2=Mnv4V2FPT0WU
A427MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXizcVllUUN3ME21MlU{PjZzIN88US=>NEDz[XhUSU6JRWK=
ChaGo-K-1NWradYxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XsN2lEPTB;NT61OlU6QSEQvF2=NYKyfYN3W0GQR1XS
PFSK-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDhRWdKSzVyPUWuOlIyQTRizszNM3;2UXNCVkeHUh?=
MLMAMo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnpTWM2OD13LkizOlA3KM7:TR?=M1KzOXNCVkeHUh?=
RVH-421NFvyZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTZwMEezN|gh|ryPMXHTRW5ITVJ?
LB1047-RCCM4eyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnOTWM2OD14LkG3OVIzKM7:TR?=NXzlc|RIW0GQR1XS
MHH-NB-11Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPhNI5uUUN3ME22MlMzPzJzIN88US=>NELJdIxUSU6JRWK=
J-RT3-T3-5M3HNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXkSXo3UUN3ME22MlY{OjlzIN88US=>NWm5PYlWW0GQR1XS
UM-UC-3MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLSTWM2OD14Lk[0N|M1KM7:TR?=NFrpR3JUSU6JRWK=
IST-SL1NITXelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfoTWM2OD14Lk[5N|Y6KM7:TR?=MUTTRW5ITVJ?
NB14MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETOVolKSzVyPU[uO|k4PjFizszNNF7Me29USU6JRWK=
NBsusSRNGC0ZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTZwOEK1NFIh|ryPNYHZS5c4W0GQR1XS
D-263MGM2fmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2n5bmlEPTB;Nj65NVA3QCEQvF2=MXLTRW5ITVJ?
NCI-H2347NEjUPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPhUWpUUUN3ME22Mlk{OjF|IN88US=>NHztb2FUSU6JRWK=
ES8NVmwSWdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fNNWlEPTB;Nj65O|U5QCEQvF2=NIPDZVNUSU6JRWK=
786-0NV72dlE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvNSGFKSzVyPUeuNFk4QDZizszNM3nIeXNCVkeHUh?=
EPLC-272HNXn5XGg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnITmZKSzVyPUeuNVYzPDZizszNMmLtV2FPT0WU
CAPAN-1NILaXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTQTWM2OD15LkK0N|U6KM7:TR?=NYfRNY05W0GQR1XS
NCI-H82MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfmXVNKSzVyPUeuNlY3PTlizszNNFjSZYJUSU6JRWK=
G-402M13ZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHiwcVlKSzVyPUeuN|AxPTFizszNNFu3[FBUSU6JRWK=
SW982NUXSbXNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzQTXVYUUN3ME23MlMxOjB|IN88US=>NWfT[GlRW0GQR1XS
OVCAR-4MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTdwM{GzNlgh|ryPMXnTRW5ITVJ?
KARPAS-299M{PtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7jS5BZUUN3ME23MlMzPjJ{IN88US=>M2X1[HNCVkeHUh?=
MIA-PaCa-2NWPhdI01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHK2bXpKSzVyPUeuN|Y5OjNizszNNV62Om8yW0GQR1XS
AU565M3i0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPYUIlKSzVyPUeuOVk5OzNizszNNVe3dlFXW0GQR1XS
GAMGMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTdwNkSxN|Eh|ryPMUHTRW5ITVJ?
HuO9MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTdwN{G3OFMh|ryPNHvBSYRUSU6JRWK=
ACNM3TFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TUbWlEPTB;Nz63OFM{KM7:TR?=NH\nPW9USU6JRWK=
RO82-W-1MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDjTWM2OD15Lke0OVM{KM7:TR?=Mn3hV2FPT0WU
NKM-1M{PVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\KPFJKSzVyPUeuO|Q6PTVizszNMmPvV2FPT0WU
CAL-12TM4\0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nrc2lEPTB;Nz65OFM2OiEQvF2=MoCwV2FPT0WU
FADUNFjPdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWWxWWxoUUN3ME24MlA{PjV2IN88US=>NFrobWJUSU6JRWK=
NCI-H28M4\SdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUK0bm1nUUN3ME24MlE3QTZ{IN88US=>NWnFeWtFW0GQR1XS
LCLC-97TM1NIjyW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRThwMkGxNlIh|ryPM4fYcHNCVkeHUh?=
CHP-134NXnmT3NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDMbGJFUUN3ME24MlI1OTh3IN88US=>MXPTRW5ITVJ?
HT-1080MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPnTWM2OD16LkK1NFk{KM7:TR?=NWnsSpR[W0GQR1XS
PC-3M{P5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TOOGlEPTB;OD6yO|M6OiEQvF2=MkniV2FPT0WU
SNU-449NX7FN5R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vUR2lEPTB;OD6yO|k{KM7:TR?=MVTTRW5ITVJ?
VA-ES-BJMlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnFR29DUUN3ME24MlM1Pjh4IN88US=>NELWXXZUSU6JRWK=
HTNUX6dWdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3K1W2lEPTB;OD6zOlQ6KM7:TR?=NWjHeoIyW0GQR1XS
HOSNHfDXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDLdFhKSzVyPUiuN|c2QDlizszNNF25TpNUSU6JRWK=
KNS-62NHj0VplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXSWVNDUUN3ME24MlM4PzZ{IN88US=>NVT6cYV3W0GQR1XS
OAW-42M2fGS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIT6eIxKSzVyPUiuPVU6PjRizszNMVfTRW5ITVJ?
A549MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTlwMEm2NVIh|ryPMXHTRW5ITVJ?
CAKI-1NIq2TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoX1TWM2OD17LkG2OlEh|ryPNVGz[XM5W0GQR1XS
HCC1937NGW1VHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEeybJpKSzVyPUmuOlk5PjVizszNMlXYV2FPT0WU
GI-ME-NNXLUcGR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTlwN{CxN|ch|ryPMXPTRW5ITVJ?
DU-4475MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvVNoJPUUN3ME25Mlk3QTN7IN88US=>NInkWo9USU6JRWK=
EM-2NYOzO492T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoX3TWM2OD1zMD6yOFI3KM7:TR?=MX7TRW5ITVJ?
NCI-H1755Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHtTWM2OD1zMD6yOFI5KM7:TR?=NUnJeG1SW0GQR1XS
NCI-H1437MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4n5PWlEPTB;MUCuOVczPSEQvF2=MoXyV2FPT0WU
VM-CUB-1NWe4UoxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;WTWM2OD1zMD62NVY1KM7:TR?=NWLCZod4W0GQR1XS
A2058MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnNd2hTUUN3ME2xNE43PDB2IN88US=>NF;U[3BUSU6JRWK=
BPH-1NFT0UGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWf6NoM{UUN3ME2xNE44OTR3IN88US=>MlrFV2FPT0WU
NB5MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\sXWlEPTB;MUCuO|U2QSEQvF2=M1zlcHNCVkeHUh?=
G-401MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTFyLke2NlYh|ryPNWDtOW54W0GQR1XS
CAL-72NV;nUnp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTFyLkiwPVQh|ryPNH3hdXZUSU6JRWK=
SK-MEL-28Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTFyLkiyNFIh|ryPNF3PdZhUSU6JRWK=
C32NYiwXGJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTFyLkizOFch|ryPMn\nV2FPT0WU
NCI-H1155MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrVTWM2OD1zMD64N|c3KM7:TR?=MmHUV2FPT0WU
BB49-HNCM{HjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTFyLki1PFYh|ryPMkXWV2FPT0WU
GMS-10MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\ZTWM2OD1zMD64PVcyKM7:TR?=MoXWV2FPT0WU
K5NHHLeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{f4[2lEPTB;MUCuPVA4OSEQvF2=NVPNWoRpW0GQR1XS
OS-RC-2Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWL6UFVpUUN3ME2xNU4xPTV7IN88US=>M4PtRnNCVkeHUh?=
HTC-C3MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTFzLkC3NVQh|ryPMnrZV2FPT0WU
LB996-RCCNEnS[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3j5d2lEPTB;MUGuNFczOyEQvF2=M37FN3NCVkeHUh?=
NCI-H1563NF;sd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrSO5dKSzVyPUGxMlExOTFizszNMVXTRW5ITVJ?
CAL-54M2q0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jVc2lEPTB;MUGuOFgyOSEQvF2=MUPTRW5ITVJ?
WM-115NUOzWItFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnu5TWM2OD1zMT62PFI1KM7:TR?=M4iweHNCVkeHUh?=
COLO-684NFTKVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\JN2hrUUN3ME2xNU44OjZ5IN88US=>M{PrOHNCVkeHUh?=
HOP-62NFz2ZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTndnhSUUN3ME2xNU44PTB6IN88US=>NF7oS2hUSU6JRWK=
NCI-H650NIrvbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTFzLki5OlEh|ryPMYTTRW5ITVJ?
TE-11M3OzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUj1W2NmUUN3ME2xNU46OzF3IN88US=>M1LKfnNCVkeHUh?=
COLO-679NWrKcHRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTFzLkm0OkDPxE1?M1fuN3NCVkeHUh?=
FTC-133NV7hdHdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLGfGVKSzVyPUGyMlAxPzZizszNMknKV2FPT0WU
D-283MEDNUj4UlRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DoXWlEPTB;MUKuNFU3QSEQvF2=M{nyc3NCVkeHUh?=
SK-PN-DWMoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHy1Xm1KSzVyPUGyMlE6ODJizszNM2LLN3NCVkeHUh?=
BALL-1NFLTTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4OyTWlEPTB;MUKuNlY3OiEQvF2=MkPxV2FPT0WU
GT3TKBMk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTF{LkOwO|Qh|ryPNV7UXlIxW0GQR1XS
HOP-92NIL5TXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTF{LkWyN|Mh|ryPMYnTRW5ITVJ?
M14MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3OTWM2OD1zMz6wN|M2KM7:TR?=MmXVV2FPT0WU
SKG-IIIaNITGNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\Pc4dKSzVyPUGzMlA2PTRizszNNXfVXnVnW0GQR1XS
BeckerMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DLeGlEPTB;MUOuNFU5KM7:TR?=M2n5dnNCVkeHUh?=
ES5NGrxN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTF|LkGzOVYh|ryPMUXTRW5ITVJ?
NCI-H2030NFXiWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvwTWM2OD1zMz6yNFYzKM7:TR?=NYjwTmpvW0GQR1XS
SNU-423NYTUbY5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXQTWM2OD1zMz6zPFEh|ryPM3e1dXNCVkeHUh?=
CP50-MEL-BMnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTF|Lk[yN|Ih|ryPM33TW3NCVkeHUh?=
NCI-H1092NIHvfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTF|Lke0O|Uh|ryPM1zrUXNCVkeHUh?=
8-MG-BANHG0XHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\sTWM2OD1zMz63OVE{KM7:TR?=M{TpVnNCVkeHUh?=
CAL-27M1mwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonnTWM2OD1zND6wO|I4KM7:TR?=NXTsUXoxW0GQR1XS
AGSMli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{T3PGlEPTB;MUSuNVMyQSEQvF2=NWLQUWtmW0GQR1XS
MZ2-MELM17pb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXVTWM2OD1zND6xOFg5KM7:TR?=MXXTRW5ITVJ?
BFTC-909MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37PWWlEPTB;MUSuOVA2PSEQvF2=MV;TRW5ITVJ?
D-566MGMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jjT2lEPTB;MUSuO|cxPiEQvF2=MYfTRW5ITVJ?
MZ7-melNXTO[|VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTF3LkGwOlch|ryPNIXEblFUSU6JRWK=
TE-5M2LsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFv3NYNKSzVyPUG1MlI{OzNizszNMk\QV2FPT0WU
647-VNXTFbFU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTF3LkK3NFUh|ryPNVHZemRjW0GQR1XS
DMS-114NULrU3J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXi5TVRDUUN3ME2xOU4{OjlzIN88US=>MonVV2FPT0WU
ME-180NIjuWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1K3UGlEPTB;MUWuOFc5OyEQvF2=NWGxfXpKW0GQR1XS
MS-1NGS2UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHwcItKSzVyPUG1MlU3OjNizszNMkj5V2FPT0WU
NUGC-3M{PEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTTTWM2OD1zNT62NlQ2KM7:TR?=NVfKfGh6W0GQR1XS
GB-1MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLuN|F{UUN3ME2xOU43PDN5IN88US=>MYHTRW5ITVJ?
LOXIMVIM4jybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkOzTWM2OD1zNT64PVE6KM7:TR?=MknDV2FPT0WU
NCI-H1304MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrUeItKSzVyPUG1Mlg6OjhizszNNWrX[mRrW0GQR1XS
KURAMOCHIM2j0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7ub2FKSzVyPUG1Mlk4OSEQvF2=MnPsV2FPT0WU
SW1783MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTF4LkC5PVMh|ryPM13kRXNCVkeHUh?=
EGI-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3O3PGlEPTB;MU[uOVM3PSEQvF2=M1XScXNCVkeHUh?=
KGNMl[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrHTWM2OD1zNj61OVg3KM7:TR?=NWSxd|JOW0GQR1XS
PANC-03-27M{O0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3v6WGlEPTB;MU[uO|Y3OiEQvF2=NHv0e29USU6JRWK=
RH-1MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILJPGpKSzVyPUG2MlgzPSEQvF2=NUDjUnZiW0GQR1XS
HT-1376NHXGS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjsTWM2OD1zNj64OFQ3KM7:TR?=NHLNNlJUSU6JRWK=
ZR-75-30NGiyXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;wTWM2OD1zNj65N|YyKM7:TR?=M3zITXNCVkeHUh?=
TI-73M12zU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfvTWM2OD1zNj65OFA5KM7:TR?=MXzTRW5ITVJ?
TK10MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\3NGlEPTB;MUeuNFA4QSEQvF2=MULTRW5ITVJ?
SW684NFzaOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrwTWM2OD1zNz6wNVU1KM7:TR?=MX3TRW5ITVJ?
RPMI-8866Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjFO5pKSzVyPUG3MlA3QTlizszNMl7DV2FPT0WU
LNCaP-Clone-FGCM2PiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTF5LkWyNFEh|ryPMnLDV2FPT0WU
NCI-H2291NEHXellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3INYwyUUN3ME2xPE41OzR3IN88US=>MW\TRW5ITVJ?
T47DM2XaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLYSoRmUUN3ME2xPE41QDhizszNMWPTRW5ITVJ?
A204NFTrbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3j0XmlEPTB;MUiuOVQ2OiEQvF2=Mk[4V2FPT0WU
HT-144NF7VfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTF6Lke0Nlch|ryPMlfVV2FPT0WU
MDA-MB-361MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF6ySWVKSzVyPUG5MlA4OTRizszNM4TaTHNCVkeHUh?=
HCC1806MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXWTWM2OD1zOT6xOVkyKM7:TR?=MUTTRW5ITVJ?
NCI-H596MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTF7Lk[zPVEh|ryPMl\pV2FPT0WU
K-562MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\lXnJTUUN3ME2xPU45QTJ4IN88US=>MnzuV2FPT0WU
D-336MGNH\tVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTF7LkmzNlIh|ryPMki1V2FPT0WU
SK-MEL-2MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlT2TWM2OD1{MD6xOVU6KM7:TR?=NEXqPWFUSU6JRWK=
HEC-1M13Yfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\0SXBKSzVyPUKwMlQ6PzhizszNNEDDd29USU6JRWK=
EW-13MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jaRmlEPTB;MkCuOVQ1OyEQvF2=NVL0PZc6W0GQR1XS
Hs-578-TM13ZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjjcJpXUUN3ME2yNE42PTh|IN88US=>MWjTRW5ITVJ?
SJSA-1NFLrPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTBSpBlUUN3ME2yNE42Pjh6IN88US=>M1rZWXNCVkeHUh?=
RCC10RGBNWjTS4hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLrTWM2OD1{MD62O|E6KM7:TR?=M1K1d3NCVkeHUh?=
LAN-6NV;hfo9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELNVFFKSzVyPUKxMlA{QTZizszNNH;ETJNUSU6JRWK=
NCI-H1048MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXj6UFNQUUN3ME2yNU4zOjV6IN88US=>MUXTRW5ITVJ?
CW-2M4The2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1S1emlEPTB;MkGuNlcxPSEQvF2=MXrTRW5ITVJ?
HCC2157NGKyfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LDVmlEPTB;MkGuN|Yh|ryPM{TSd3NCVkeHUh?=
EW-22MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTJzLkO3OkDPxE1?NF2xdZNUSU6JRWK=
A253MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmD5TWM2OD1{MT60OFgyKM7:TR?=NYXnT3B{W0GQR1XS
BE-13MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHu2TlBKSzVyPUKxMlYyOTNizszNMorDV2FPT0WU
KINGS-1MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULvOHhtUUN3ME2yNU43OzF4IN88US=>NXvxbYVMW0GQR1XS
ETK-1NXjKPGpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX65PYQxUUN3ME2yNU45OTV{IN88US=>Ml\OV2FPT0WU
NCI-H2452NWi5bXVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkP5TWM2OD1{MT64OlQ4KM7:TR?=M3KyXHNCVkeHUh?=
HPAF-IIMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTJzLki5NlMh|ryPNYC3c5lFW0GQR1XS
D-542MGMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTJzLkmwOlkh|ryPMWTTRW5ITVJ?
NCI-H630NEC4cFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXDTWM2OD1{Mj6wNlk3KM7:TR?=MWPTRW5ITVJ?
TGBC11TKBMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfFcINKSzVyPUKyMlA1QSEQvF2=NITBVY5USU6JRWK=
BCPAPMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXPU|NKSzVyPUKyMlYyOSEQvF2=MnPGV2FPT0WU
HLEM3zadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PIN2lEPTB;MkKuOlk4KM7:TR?=MVvTRW5ITVJ?
NCI-H727NELKVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkn1TWM2OD1{Mj63N|Uh|ryPMkOwV2FPT0WU
RDM1G2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTJ{Lke1NVgh|ryPMVXTRW5ITVJ?
NCI-H522NUTxTGRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfITWM2OD1{Mj64OFMyKM7:TR?=MmDMV2FPT0WU
CGTH-W-1M{DV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nqSGlEPTB;MkOuNFY1OSEQvF2=NIPhTldUSU6JRWK=
SK-LU-1MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnMZmE3UUN3ME2yN{41Pjh|IN88US=>NUjMbXVpW0GQR1XS
BB65-RCCNIrXdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHaVlBMUUN3ME2yN{44QDZ|IN88US=>NVKxV41NW0GQR1XS
HSC-3MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHrS4lKSzVyPUKzMlg2OjdizszNNXHIOnFKW0GQR1XS
SK-MES-1MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfBTWM2OD1{ND6wNVYyKM7:TR?=NIXndVRUSU6JRWK=
DBNHPE[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrtTWM2OD1{ND6xNFI5KM7:TR?=NEL0fHBUSU6JRWK=
HO-1-N-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;HdoNwUUN3ME2yOE4{ODl|IN88US=>MmfnV2FPT0WU
MKN1NX\EdlFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HsfmlEPTB;MkSuOlgh|ryPMoDLV2FPT0WU
MN-60NYi5eZZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3CTWM2OD1{ND64OVE6KM7:TR?=MofBV2FPT0WU
8505CNIHyZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3MNWpTUUN3ME2yOU4yQDR3IN88US=>M4TwUXNCVkeHUh?=
COLO-320-HSRNV\HRodCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzR[nZKSzVyPUK1MlIzODhizszNMl[wV2FPT0WU
BB30-HNCNUHET4kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnaO4dzUUN3ME2yOU4zPDh|IN88US=>NF;zb41USU6JRWK=
KM12NITYW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXiycnp2UUN3ME2yOU42QDB5IN88US=>NVXYUJMxW0GQR1XS
NB13M3fmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTJ3LkW4PVgh|ryPMlHyV2FPT0WU
HCC2998NF70ZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DCT2lEPTB;Mk[uNFI5OyEQvF2=M4[2XnNCVkeHUh?=
U-118-MGM2nxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULIdlloUUN3ME2yOk4xQDB6IN88US=>MkewV2FPT0WU
NB10NW\IOHhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XYcGlEPTB;Mk[uNlM1KM7:TR?=NX;DVGY1W0GQR1XS
SK-LMS-1NXWzcoZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jWVmlEPTB;MkeuNFcxPCEQvF2=MX3TRW5ITVJ?
SW1573NU\QbJVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLUVIp4UUN3ME2yO{4yOSEQvF2=NWmzOnl2W0GQR1XS
LB373-MEL-DMlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYT5N|hJUUN3ME2yO{4yOjl2IN88US=>NEOxe|BUSU6JRWK=
DK-MGNEHoV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TCdGlEPTB;MkeuNVgyPyEQvF2=MlXLV2FPT0WU
RMG-IM4fiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\SWYJNUUN3ME2yO{4zODJ7IN88US=>Mnm5V2FPT0WU
SW1088M2f2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXW1boJQUUN3ME2yO{42ODR{IN88US=>M37FZ3NCVkeHUh?=
SK-OV-3NY\jU2M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXUT3hmUUN3ME2yO{44PTl|IN88US=>NYHhO3gzW0GQR1XS
KP-N-YNNEPTVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTJ5LkiwOFMh|ryPM4DnTnNCVkeHUh?=
RPMI-7951M{fXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvCTWM2OD1{OD6yOFU3KM7:TR?=MnzNV2FPT0WU
CaR-1MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIq3O2lKSzVyPUK4MlU2QDJizszNNIDxZWRUSU6JRWK=
MKN7MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTJ6LkW5OlQh|ryPM3Lz[3NCVkeHUh?=
CHP-212MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7RTWM2OD1{OD63OFAyKM7:TR?=MWXTRW5ITVJ?
KYSE-450MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3Hhb2lEPTB;MkiuPFA6OSEQvF2=NXHiPFU1W0GQR1XS
RXF393NEHteYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXud|VKSzVyPUK5MlI6ODZizszNMVXTRW5ITVJ?
P30-OHKM{i5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPaW2VKSzVyPUK5MlMxPDhizszNNGLQNVJUSU6JRWK=
Ca9-22M{nTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nsfWlEPTB;MkmuOFI6QSEQvF2=M1fhfHNCVkeHUh?=
RT-112MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XPeWlEPTB;MkmuOFYyOSEQvF2=NIjETXBUSU6JRWK=
ES1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3H2WmlEPTB;MkmuPFU1PCEQvF2=MW\TRW5ITVJ?
HCE-4MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrJTWM2OD1{OT64O|g3KM7:TR?=M1nIcnNCVkeHUh?=
AM-38NWDabmpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXtc2xLUUN3ME2zNE4xPjB4IN88US=>M{DyfnNCVkeHUh?=
AsPC-1MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jpZWlEPTB;M{CuPFA2OyEQvF2=NGG0TIVUSU6JRWK=
TE-9M1nmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrRfZdKSzVyPUOwMlg4OzdizszNMkD0V2FPT0WU
HuP-T4MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fSWWlEPTB;M{CuPVY{QCEQvF2=NWOyb4hiW0GQR1XS
LB2518-MELMlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTNzLkC3OFQh|ryPNUL1WZV4W0GQR1XS
NCI-H1703NH62VWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrKTWM2OD1|MT6wPVA2KM7:TR?=MXnTRW5ITVJ?
NCI-H2228MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXh[pZWUUN3ME2zNU41PjVzIN88US=>NFvkSJBUSU6JRWK=
SCC-4NYnkeXJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTNzLkmxPFEh|ryPM4XRfHNCVkeHUh?=
KNS-81-FDM1XI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXJTWM2OD1|Mj6wNVI5KM7:TR?=M3LONXNCVkeHUh?=
NTERA-S-cl-D1M325dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlu1TWM2OD1|Mj6wO|M6KM7:TR?=NUXFOWhqW0GQR1XS
DaoyMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTN{LkC4N|gh|ryPNEPlN|JUSU6JRWK=
ES4NI[2TVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTN{LkO5NlIh|ryPM13rdXNCVkeHUh?=
MHH-ES-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHv4V2lKSzVyPUOyMlQ5PzJizszNNFvyd2NUSU6JRWK=
C-33-AMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknHTWM2OD1|Mj63O|I5KM7:TR?=MUPTRW5ITVJ?
BHYM4\tXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTN{Lkm0PVUh|ryPNXn3PI44W0GQR1XS
Detroit562Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTN|Lk[2OVch|ryPM4\wcHNCVkeHUh?=
EW-1NGPtVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHH1bpJKSzVyPUOzMlk{OjJizszNMXLTRW5ITVJ?
NCI-H1395MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLCTWM2OD1|ND6wO|k6KM7:TR?=NWT1e5BUW0GQR1XS
KM-H2MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLLN|l2UUN3ME2zOk41PzR|IN88US=>Mnj0V2FPT0WU
NCI-H520NXLXZYd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU[4U4JbUUN3ME2zOk44PTRzIN88US=>MnTUV2FPT0WU
D-392MGM4eyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTN5LkOzOFQh|ryPNWrtR|hCW0GQR1XS
NOMO-1MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTN5LkiwPFkh|ryPMXrTRW5ITVJ?
TE-6NIDTR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrLT2xFUUN3ME2zPE4yOjRizszNNHHlRldUSU6JRWK=
HT-3NU\TV5ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPkTWM2OD1|OD60OFM3KM7:TR?=NIm0RmNUSU6JRWK=
RPMI-8226NYLkUHhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPrTWM2OD1|OD65OVE6KM7:TR?=MWDTRW5ITVJ?
U251MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DicGlEPTB;M{muNFEzPCEQvF2=MmC3V2FPT0WU
GCTM3rBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\RenhKSzVyPUO5MlE5PTJizszNNF7hU2NUSU6JRWK=
A431MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTN7LkG4PVQh|ryPM{HM[nNCVkeHUh?=
TE-12Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTN7LkK0OFgh|ryPMY\TRW5ITVJ?
HMV-IINHHZUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjXeFBWUUN3ME2zPU42ODR5IN88US=>M{PWdXNCVkeHUh?=
IST-MES1NVnkWG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTLTWM2OD12MD6xOVAzKM7:TR?=M1XjS3NCVkeHUh?=
SW13M{Tsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTzTWM2OD12MD61NVkh|ryPNV:5WoRxW0GQR1XS
SF295NXzHR4p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPYTWM2OD12MD64NFY3KM7:TR?=M1:0OXNCVkeHUh?=
MDA-MB-157MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfoN4ZCUUN3ME20NE46PDZ{IN88US=>NICwb3dUSU6JRWK=
TE-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPlZ4ZTUUN3ME20NU45PzF2IN88US=>MWDTRW5ITVJ?
HuCCT1NWTUUpdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7O[JNwUUN3ME20Nk42Ojh7IN88US=>MoLPV2FPT0WU
KYSE-510MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;kO2lEPTB;NEOuNVc2PCEQvF2=M1nsV3NCVkeHUh?=
NCI-H358NV36SItsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTR2LkCzNFQh|ryPM1P3ZnNCVkeHUh?=
SW900Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHodZVKSzVyPUS0MlA4PThizszNM{[0S3NCVkeHUh?=
CAS-1NUHDV21FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;HTWM2OD12ND6wPVkyKM7:TR?=M1LNdnNCVkeHUh?=
TE-8NF;KNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHyxdnlKSzVyPUS0MlU3PThizszNM4W1[3NCVkeHUh?=
P12-ICHIKAWANXfqbIFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLZfplKSzVyPUS0MlYyOTJizszNNHfQSFhUSU6JRWK=
YKG-1MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LO[WlEPTB;NESuO|gyKM7:TR?=MoiwV2FPT0WU
SNU-C2BMkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfEXlVKSzVyPUS0Mlc6ODNizszNMkfYV2FPT0WU
LCLC-103HNYHaXnJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTR2Lki3NFMh|ryPMnXnV2FPT0WU
U-87-MGMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmG5TWM2OD12NT6xNFIzKM7:TR?=MUjTRW5ITVJ?
HAL-01Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\KTWM2OD12NT6xN|c6KM7:TR?=MXHTRW5ITVJ?
OVCAR-8M1Tvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXO5bJN3UUN3ME20OU4{PTZ2IN88US=>NV3ZOYg2W0GQR1XS
KYSE-150MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4CxTWlEPTB;NEeuNVA2OiEQvF2=NXPENW1HW0GQR1XS
OE33NHzr[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfTTWM2OD12Nz6xOFI6KM7:TR?=NXL1eHR3W0GQR1XS
CAL-62NV;RSoplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTR5LkSwOlgh|ryPMXTTRW5ITVJ?
TCCSUPMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITK[JpKSzVyPUS3MlYzPjRizszNM2LNNHNCVkeHUh?=
H4NHrWdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7TTWM2OD12Nz62OlIyKM7:TR?=MXHTRW5ITVJ?
CP66-MELNXPOfI06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjVOHZVUUN3ME20PE4xPzB2IN88US=>M4fGOHNCVkeHUh?=
SNB75NEnvUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7h[WVKSzVyPUS4MlE5PzRizszNMk[yV2FPT0WU
Mo-TMnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTKTWM2OD12OD6yO|kh|ryPMn7UV2FPT0WU
BT-549NFXmRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XLUGlEPTB;NEiuN|czQSEQvF2=MVXTRW5ITVJ?
IGR-1NYrqe|QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnX0TWM2OD12OD62OlQ2KM7:TR?=MmPBV2FPT0WU
NCI-H1299MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\mXW9OUUN3ME20PE44OjR6IN88US=>Mm[2V2FPT0WU
ALL-POMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTB[mF5UUN3ME20PU46OjZ6IN88US=>MmX3V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. [2]
Features

Protocol(Only for Reference)

Cell Assay: [2]

Cell lines SW620, LoVo, V3-YAC and V3 cells
Concentrations 0.5 μM or 1 μM
Incubation Time 17 hours
Method The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min 137Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 105 per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

Animal Study: [2]

Animal Models Female rude mice bearing SW620 xenografts
Formulation Sterile 0.9% sodium chloride solution
Dosages 10 mg/kg
Administration Intraperitoneally administrated

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Leahy JJ, et al. Bioorg Med Chem Lett, 2004, 14(24), 6083-6087.

[2] Zhao Y, et al. Cancer Res, 2006 , 66(10), 5354-5362.

view more

Chemical Information

Download NU7441 (KU-57788) SDF
Molecular Weight (MW) 413.49
Formula

C25H19NO3S

CAS No. 503468-95-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL (7.25 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4H-1-Benzopyran-4-one, 8-(4-dibenzothienyl)-2-(4-morpholinyl)-

Customer Product Validation (4)


Click to enlarge
Rating
Source Nucleic Acids Res 2013 41(15), 7378-86. NU7441 (KU-57788) purchased from Selleck
Method EU Immunofluorescence
Cell Lines A2780 ovarian cancer cells
Concentrations 1 uM
Incubation Time 1 h
Results It performed similar experiments using specific inhibitors of DNA-PK. Treatment with Nu7026 or Nu7441 before cisplatin significantly prevented inhibition of rRNA synthesis.

Click to enlarge
Rating
Source Nucleic Acids Res 2013 41, 10157-69. NU7441 (KU-57788) purchased from Selleck
Method Confocal immunostaining
Cell Lines 293T
Concentrations
Incubation Time 30min ,60min
Results the number of IRIFs was reduced significantly in p18CycE-expressing HEK 293T cells compared with parental cells. Pharmacological inhibition of ATM with KU55933 Revealed that S25-53BP1 phosphorylation was ATM-dependent in these cells as IRIFs of S25-53BP1 were abolished in both parental, as well as p18CycE-expressing cells.

Click to enlarge
Rating
Source Toxicol Sci 2014 10.1093/toxsci/kfu207. NU7441 (KU-57788) purchased from Selleck
Method Western blot
Cell Lines H460 cells
Concentrations 1, 3, 10 uM
Incubation Time 1 h
Results It tested 3 concentrations of 2 DNAPK inhibitors (NU7026 and NU7441) for their off-target effects on ATM and ATR signaling in camptothecin-exposed cells. We found that only the highest dose of 60 uM NU7026 clearly diminished ATR activity as evidenced by a lower CHK1 phosphorylation. All doses of both inhibitors eliminated activating autophosphorylation of DNAPK at Ser2056.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. NU7441 (KU-57788) purchased from Selleck
Method
Cell Lines A549 cells
Concentrations 0-10 μM
Incubation Time 3 h
Results NU-7441 treatment resulted in a reduction of AKT phosphorylation.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA-PK Products

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • NU7026

    NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

  • KU-0060648

    KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • CHIR-99021 (CT99021) HCl

    CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

Recently Viewed Items

Tags: buy NU7441 (KU-57788) | NU7441 (KU-57788) supplier | purchase NU7441 (KU-57788) | NU7441 (KU-57788) cost | NU7441 (KU-57788) manufacturer | order NU7441 (KU-57788) | NU7441 (KU-57788) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us